U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C17H14N2O3
Molecular Weight 294.3047
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ROSOXACIN

SMILES

CCN1C=C(C(O)=O)C(=O)C2=C1C=C(C=C2)C3=CC=NC=C3

InChI

InChIKey=XBPZXDSZHPDXQU-UHFFFAOYSA-N
InChI=1S/C17H14N2O3/c1-2-19-10-14(17(21)22)16(20)13-4-3-12(9-15(13)19)11-5-7-18-8-6-11/h3-10H,2H2,1H3,(H,21,22)

HIDE SMILES / InChI

Description

Rosoxacin, a quinolone derivative, is an antibiotic, which is used for the treatment of uncomplicated acute gonococcal urethritis. Administration of rosoxacin is an effective regimen for the therapy of chancroid and is a reasonable alternative to other short-course regimens. The drug binds to and inhibits two enzymes topoisomerase II (DNA gyrase), which is required for bacterial DNA replication, transcription, repair, and recombination.

Approval Year

Unknown
149124
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8504
PubMed

PubMed

TitleDatePubMed
Selective Spectrophotometric and Spectrofluorometric Methods for the Determination of Amantadine Hydrochloride in Capsules and Plasma via Derivatization with 1,2-Naphthoquinone-4-sulphonate.
2009
A selective spectrophotometric method for determination of rosoxacin antibiotic using sodium nitroprusside as a chromogenic reagent.
2008-04
Pharmacy clerks' prescribing practices for STD patients in Porto Alegre, Brazil: missed opportunities for improving STD control.
2004-05
Anti-toxoplasma activities of 24 quinolones and fluoroquinolones in vitro: prediction of activity by molecular topology and virtual computational techniques.
2000-10
Prediction of quinolone activity against Mycobacterium avium by molecular topology and virtual computational screening.
2000-10
Antiviral properties of 3-quinolinecarboxamides: a series of novel non-nucleoside antiherpetic agents.
1997-05
Anti-Mycobacterium avium activity of quinolones: in vitro activities.
1993-09
Patents

Patents

20010044416
23

Sample Use Guides

In Vivo Use Guide
a single 300 mg capsule
Route of Administration: Oral
Name Type Language
ROSOXACIN
INN   MART.   MI   USAN   WHO-DD  
USAN   INN  
Official Name English
ERACINE
Preferred Name English
rosoxacin [INN]
Common Name English
ERADICIN
Brand Name English
ROSOXACIN [USAN]
Common Name English
ROSOXACIN [MI]
Common Name English
1-Ethyl-1,4-dihydro-4-oxo-7-(4-pyridyl)-3-quinolinecarboxylic acid
Systematic Name English
Rosoxacin [WHO-DD]
Common Name English
ACROSOXACIN
Common Name English
WINURON
Brand Name English
WIN 35,213
Code English
ROSOXACIN [MART.]
Common Name English
NSC-146617
Code English
WIN-35213
Code English
ERADACIL
Brand Name English
WINOXACIN
Brand Name English
3-QUINOLINECARBOXYLIC ACID, 1-ETHYL-1,4-DIHYDRO-4-OXO-7-(4-PYRIDINYL)-
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C795
Created by admin on Mon Mar 31 17:50:38 GMT 2025 , Edited by admin on Mon Mar 31 17:50:38 GMT 2025
WHO-ATC J01MB01
Created by admin on Mon Mar 31 17:50:38 GMT 2025 , Edited by admin on Mon Mar 31 17:50:38 GMT 2025
WHO-VATC QJ01MB01
Created by admin on Mon Mar 31 17:50:38 GMT 2025 , Edited by admin on Mon Mar 31 17:50:38 GMT 2025
Code System Code Type Description
EVMPD
SUB10389MIG
Created by admin on Mon Mar 31 17:50:38 GMT 2025 , Edited by admin on Mon Mar 31 17:50:38 GMT 2025
PRIMARY
FDA UNII
3Y1OT3J4NW
Created by admin on Mon Mar 31 17:50:38 GMT 2025 , Edited by admin on Mon Mar 31 17:50:38 GMT 2025
PRIMARY
EPA CompTox
DTXSID90193091
Created by admin on Mon Mar 31 17:50:38 GMT 2025 , Edited by admin on Mon Mar 31 17:50:38 GMT 2025
PRIMARY
MERCK INDEX
m9670
Created by admin on Mon Mar 31 17:50:38 GMT 2025 , Edited by admin on Mon Mar 31 17:50:38 GMT 2025
PRIMARY Merck Index
SMS_ID
100000084362
Created by admin on Mon Mar 31 17:50:38 GMT 2025 , Edited by admin on Mon Mar 31 17:50:38 GMT 2025
PRIMARY
INN
3903
Created by admin on Mon Mar 31 17:50:38 GMT 2025 , Edited by admin on Mon Mar 31 17:50:38 GMT 2025
PRIMARY
RXCUI
35797
Created by admin on Mon Mar 31 17:50:38 GMT 2025 , Edited by admin on Mon Mar 31 17:50:38 GMT 2025
PRIMARY RxNorm
ChEMBL
CHEMBL291157
Created by admin on Mon Mar 31 17:50:38 GMT 2025 , Edited by admin on Mon Mar 31 17:50:38 GMT 2025
PRIMARY
ECHA (EC/EINECS)
254-758-4
Created by admin on Mon Mar 31 17:50:38 GMT 2025 , Edited by admin on Mon Mar 31 17:50:38 GMT 2025
PRIMARY
DRUG BANK
DB00817
Created by admin on Mon Mar 31 17:50:38 GMT 2025 , Edited by admin on Mon Mar 31 17:50:38 GMT 2025
PRIMARY
NCI_THESAURUS
C76232
Created by admin on Mon Mar 31 17:50:38 GMT 2025 , Edited by admin on Mon Mar 31 17:50:38 GMT 2025
PRIMARY
WIKIPEDIA
ROSOXACIN
Created by admin on Mon Mar 31 17:50:38 GMT 2025 , Edited by admin on Mon Mar 31 17:50:38 GMT 2025
PRIMARY
CAS
40034-42-2
Created by admin on Mon Mar 31 17:50:38 GMT 2025 , Edited by admin on Mon Mar 31 17:50:38 GMT 2025
PRIMARY
DRUG CENTRAL
83
Created by admin on Mon Mar 31 17:50:38 GMT 2025 , Edited by admin on Mon Mar 31 17:50:38 GMT 2025
PRIMARY
NSC
146617
Created by admin on Mon Mar 31 17:50:38 GMT 2025 , Edited by admin on Mon Mar 31 17:50:38 GMT 2025
PRIMARY
PUBCHEM
287180
Created by admin on Mon Mar 31 17:50:38 GMT 2025 , Edited by admin on Mon Mar 31 17:50:38 GMT 2025
PRIMARY
ACTIVE MOIETY
Structure of ROSOXACIN
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966